BioSpace News Archive

Eyenovia, Inc. announced that the company will be delivering a presentation at the annual OCTANE Ophthalmology Tech Forum 2023, which is being held June 8-9 in Newport Beach, CA.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th:

Catalyst Pharmaceuticals, Inc. reported positive momentum for the second quarter of 2023 and reaffirmed its full-year 2023 total revenue guidance of between $375 million and $385 million, representing a 75% to 80% increase in total revenues compared to 2022.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that members of its management team will participate in the following upcoming investor conferences.

CareDx, Inc. announced a leading presence at the 2023 American Transplant Congress with 65 scientific presentations.

Eikon Therapeutics, Inc. today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review.

IO Biotech announced that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate.

Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced that management will participate in the following upcoming investor conferences.

Dyadic International, Inc. announced that its management will be participating in the following events during the month of June.

IMPACT Therapeutics and Eikon Therapeutics today announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter into Phase I clinical study in 2023.